Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could spot deadly lung disease years earlier

NCT ID NCT05452889

Diagnosis Sponsor: Stephen Y. Chan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether a special PET scan tracer, 18F-fluoroglutamine, can detect pulmonary arterial hypertension (PAH) earlier and more accurately. PAH is a serious disease of the lung's blood vessels that often goes undiagnosed for years. The study will scan 71 adults with and without PAH to see if the tracer highlights diseased areas in the lungs and heart.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-fluoroglutamine (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors detect pulmonary arterial hypertension earlier, potentially leading to faster treatment and better outcomes.
What could go wrong
This is a very early, small study (71 participants) focused on imaging, not treatment. The tracer may not reliably distinguish disease from healthy tissue, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 71 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cases: 1. Age between 18-75 years old 2. Confirmed diagnosis of SSc-PAH / SSc-eiPAH/IPAH/ by right heart catheterization. And Scleroderma with no PAH confirmand by echo. Controls: 1. Age between 18-75 years old 2. Individuals who are at low risk for current or future cardiovascular or pulmonary symptoms or diseases Exclusion Criteria: Cases: 1. Smoking 2. Pregnant/ breast feeding women 3. Children under 18 4. Inability to read and understand the informed consent 5. History of CT contrast allergy 6. Inability to lie down for long period of time 7. Having claustrophobic 8. History of radiation exposure at workplace 9. Consuming more than 2-3 alcoholic drinks a week 10. Working previously in any of the following "cool miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand" 11. Any medical conditions involving the heart or lungs that would make participation in the study unsafe in the opinion of the PI. Controls: 1. Smoking 2. Pregnant/ breast feeding women 3. Children under 18 4. Inability to read and understand the informed consent 5. History of CT contrast allergy. 6. Inability to lie down for long period of time 7. Having claustrophobic 8. History of radiation exposure at workplace 9. Consuming more than 2-3 alcoholic drinks a week 10. Working previously in any of the following "coal miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand" 11. Any medical conditions involving the heart or lungs or that would make participation in the study unsafe in the opinion of the PI. 12. Family history of Pulmonary Hypertension or Scleroderma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease idiopathic pulmonary arterial hypertension pulmonary arterial hypertension pulmonary hypertension pulmonary systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Montefiore Hospital Clinical and Translational Research Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.